Results for noradrenergic translation from English to Maltese

this may be due to the noradrenergic effect of duloxetine.
dan jista’ jseħħ minħabba l-effett noradrinerġiku ta’ duloxetine.

dexmedetomidine is a potent and selective α2-adrenoceptor agonist that inhibits the release of noradrenaline from noradrenergic neurons.
dexmedetomidine huwa α2-adrenoceptor agonist qawwi u selettiv li jimblokka l-ħruġ ta’ noradrenalina minn newroni noradrenerġiċi.

the sedative effects are mediated through decreased firing of locus coeruleus, the predominant noradrenergic nucleus, situated in the brainstem.
l-effetti sedattivi huma kkaġunati permezz ta’ tnaqqis ta’ reħa mil-locus coeruleus, in-nukleu noradrinerġiku predominanti, li jinsab fis-sinsla tal-moħħ.

animal studies indicate that noradrenergic and serotonergic neurons are coupled (i.e. limit the activity of each other)
xi trattamenti jistgħu jintużaw ukoll għal perijodu qasir biex jgħinu lil individwi jieqfu jieħdu d-drogi kollha.

patients on antidepressants which affect noradrenergic transmission (e.g. tricyclic antidepressants and mianserin) (see section 4.5)
pazjenti fuq antidepressanti li jaffettwaw it-trasmissjoni noradrinerġika (eż. antidepressanti triċikliċi u mianserin) (ara sezzjoni 4.5)

over time, noradrenergic and serotonergic neurons become autonomous and hyper-reactive to external stimuli and arguably this druginduced long-term uncoupling explains dysfunctions in motivation and in the ability to inhibit impulses.
maż-żmien, in-newroni noradrenerġiċi u serotonerġiċi jsiru awtonomi u reattivi żżejjed għall-istimuli esterni u b’mod diskutibbli din is-separazzjoni fuq żmien twil ikkaġunata mid-drogi tista’ tispjega l-funzjonament ħażin filmotivazzjoni u fl-abilità ta’ inibizzjoni ta’ agir skond ix-xewqa tal-mument.

dexmedetomidine is a potent and selective alpha-2 adrenoceptor agonist that inhibits the release of noradrenaline (na) from noradrenergic neurons, blocks the startle reflex and thus counteracts arousal.
dexmedetomidine hu agonist potenti u selettiv ta' alpha-2 adrenoceptor li jinibixxi l-ħruġ ta' noradrenaline (na) minn newroni noradrenerġiċi, jimblokka l-istartle reflex u b'hekk iservi ta' kontrobilanċ għall-biża'.

mirvaso is contraindicated in patients receiving monoamine oxidase (mao) inhibitor therapy and patients on tricyclic or tetracyclic antidepressants which affect noradrenergic transmission (see section 4.3).
mirvaso huwa kontraindikat f’pazjenti li jirċievu terapija ta’ inibituri ta’ monoamine oxidase (mao) u pazjenti fuq antidepressanti triċikliċi jew tetraċikliċi li jaffettwaw it-trasmissjoni noradrinerġika (ara sezzjoni 4.3).